Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Strategic Spin-off | Explore Medtronic's plans to separate its Diabetes segment, a move analysts believe could create significant shareholder value and improve growth prospects |
Cardiovascular Catalysts | Delve into the potential of Pulsed Field Ablation and Renal Denervation technologies, driving Medtronic's cardiovascular segment towards sustained growth |
Robotic Surgery Frontie | Learn about Medtronic's Hugo surgical robot system, poised to challenge established players in the competitive surgical robotics market |
Financial Outlook | Analysts project EPS of $5.52 for FY26 and $5.94 for FY27, with an average price target around $102, reflecting optimism despite near-term challenges |
Metrics to compare | MDT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDTPeersSector | |
---|---|---|---|---|
P/E Ratio | 25.2x | 10.4x | −0.5x | |
PEG Ratio | 0.81 | −0.19 | 0.00 | |
Price/Book | 2.4x | 2.0x | 2.6x | |
Price / LTM Sales | 3.5x | 1.1x | 3.2x | |
Upside (Analyst Target) | 4.2% | 20.7% | 42.7% | |
Fair Value Upside | Unlock | 18.5% | 5.8% | Unlock |